Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
2 Acute myeloid leukemia 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
3 Adipocytokine signaling pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
4 Adipocytokine signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
5 Adrenergic signaling in cardiomyocytes 💬
2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
6 Adrenergic signaling in cardiomyocytes 💬
2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
7 Alzheimer disease 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
8 Alzheimer disease 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
9 AMPK signaling pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
10 AMPK signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
11 Amyotrophic lateral sclerosis 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
12 Amyotrophic lateral sclerosis 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
13 Apelin signaling pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
14 Apelin signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
15 Autophagy - animal 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
16 Autophagy - animal 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
17 Autophagy - other 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
18 Autophagy - other 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
19 Breast cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
20 Breast cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
21 Calcium signaling pathway 💬
2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
22 Calcium signaling pathway 💬
2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
23 cAMP signaling pathway 💬
2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
24 cAMP signaling pathway 💬
2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
25 Cellular senescence 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
26 Cellular senescence 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
27 Central carbon metabolism in cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
28 Central carbon metabolism in cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
29 cGMP-PKG signaling pathway 💬
2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
30 cGMP-PKG signaling pathway 💬
2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
31 Chemical carcinogenesis - receptor activation 💬
2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
32 Chemical carcinogenesis - receptor activation 💬
2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
33 Chemical carcinogenesis - receptor activation 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
34 Chemical carcinogenesis - receptor activation 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
35 Choline metabolism in cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
36 Choline metabolism in cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
37 Colorectal cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
38 Colorectal cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
39 Diabetic cardiomyopathy 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
40 Diabetic cardiomyopathy 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
41 Dilated cardiomyopathy 💬
1件: ADRB1 💬 D00378 💬 Timolol 2件: 157, 227 💬
42 Dilated cardiomyopathy 💬
1件: ADRB1 💬 D08600 💬 Timolol 2件: 157, 227 💬
43 EGFR tyrosine kinase inhibitor resistance 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
44 EGFR tyrosine kinase inhibitor resistance 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
45 Endocrine resistance 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
46 Endocrine resistance 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
47 ErbB signaling pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
48 ErbB signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
49 Gap junction 💬
1件: ADRB1 💬 D00378 💬 Timolol 2件: 157, 227 💬
50 Gap junction 💬
1件: ADRB1 💬 D08600 💬 Timolol 2件: 157, 227 💬
51 Gastric cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
52 Gastric cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
53 Glioma 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
54 Glioma 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
55 Growth hormone synthesis, secretion and action 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
56 Growth hormone synthesis, secretion and action 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
57 Hepatocellular carcinoma 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
58 Hepatocellular carcinoma 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
59 Herpes simplex virus 1 infection 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
60 Herpes simplex virus 1 infection 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
61 HIF-1 signaling pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
62 HIF-1 signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
63 Human cytomegalovirus infection 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
64 Human cytomegalovirus infection 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
65 Human immunodeficiency virus 1 infection 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
66 Human immunodeficiency virus 1 infection 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
67 Human papillomavirus infection 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
68 Human papillomavirus infection 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
69 Huntington disease 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
70 Huntington disease 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
71 Insulin resistance 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
72 Insulin resistance 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
73 Insulin signaling pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
74 Insulin signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
75 JAK-STAT signaling pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
76 JAK-STAT signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
77 Kaposi sarcoma-associated herpesvirus infection 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
78 Kaposi sarcoma-associated herpesvirus infection 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
79 Longevity regulating pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
80 Longevity regulating pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
81 Longevity regulating pathway - multiple species 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
82 Longevity regulating pathway - multiple species 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
83 MicroRNAs in cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
84 MicroRNAs in cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
85 mTOR signaling pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
86 mTOR signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
87 Neuroactive ligand-receptor interaction 💬
2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
88 Neuroactive ligand-receptor interaction 💬
2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
89 Neuroactive ligand-receptor interaction 💬
2件: CNR1, CNR2 💬 D10915 💬 Cannabidiol 20件:  2 ,  6 ,  8 , 13, 36, 46, 51, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271 💬
90 Neutrophil extracellular trap formation 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
91 Neutrophil extracellular trap formation 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
92 Pancreatic cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
93 Pancreatic cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
94 Pathways in cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
95 Pathways in cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
96 Pathways of neurodegeneration - multiple diseases 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
97 Pathways of neurodegeneration - multiple diseases 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
98 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
99 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
100 Phospholipase D signaling pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
101 Phospholipase D signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
102 PI3K-Akt signaling pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
103 PI3K-Akt signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
104 Prostate cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
105 Prostate cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 💬
106 Proteoglycans in cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
107